MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-27-2024
Ampio Pharmaceuticals Operating Income 2011-2026 | AMPE
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | -33.3 M | -39.1 M | -24 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -24 M | -39.1 M | -32.1 M |
Quarterly Operating Income Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.67 M | - | - | - | -9.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.67 M | -9.5 M | -8.58 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Processa Pharmaceuticals
PCSA
|
-14 M | $ 2.3 | -1.29 % | $ 3.01 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 220.9 | 2.49 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 19.57 | 1.77 % | $ 915 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Phathom Pharmaceuticals
PHAT
|
-160 M | $ 10.47 | 4.08 % | $ 763 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Cara Therapeutics
CARA
|
-121 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Pliant Therapeutics
PLRX
|
-156 M | $ 1.31 | 2.34 % | $ 80.4 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
-86.2 M | $ 1.37 | -1.44 % | $ 72 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.33 | 0.76 % | $ 339 M | Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-85.3 M | $ 8.31 | 1.59 % | $ 111 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-665 M | $ 47.09 | 1.42 % | $ 4.23 B |  Schweiz |
 |
Cyclacel Pharmaceuticals
CYCC
|
-12 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
-130 M | - | - | $ 3.74 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
-105 M | $ 3.26 | 4.49 % | $ 251 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-4.12 M | - | - | $ 2.02 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
-57.2 M | $ 1.58 | 6.04 % | $ 99.5 M |  Niderland |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
-189 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Palatin Technologies
PTN
|
-17.5 M | $ 21.0 | 5.79 % | $ 19.5 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Pulmatrix
PULM
|
-5.17 M | $ 2.12 | -1.4 % | $ 7.74 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-38.2 M | $ 4.53 | 5.1 % | $ 868 M | Canada |
 |
Homology Medicines
FIXX
|
16.9 M | - | 0.77 % | $ 53.4 M | USA |